Tag: Diagnostics

IVD Market: SWOT Analysis

The main purpose of in vitro diagnostic solutions is to perform non-invasive / minimally invasive test procedures in order to detect a variety of health conditions using samples, such as blood, tissue or urine. Such tests help to diagnose health conditions, monitor treatments, perform disease screening and aid in early diagnosis of diseases. The process

Oncology Molecular Diagnostics Market: Solutions Driving Early Cancer Detection

Globally, cancer is one of the leading causes of death, however advancements in molecular diagnostics have enabled early detection and improved outcomes. Early detection of cancer is crucial as it improves the treatment process and increases the chances of survival. This article explores the role of molecular diagnostics in early cancer detection, highlighting the benefits

Molecular Diagnostic Tests: The Unsung Hero of Precise Clinical Decision Making

Molecular diagnostic tests are advanced techniques and tools used to analyze biological markers in the genome and proteome. These diagnostic solutions are essential for detecting and monitoring diseases, identifying genetic abnormalities, and guiding personalized treatment plans. The primary technologies used in the molecular diagnostics domain include polymerase chain reaction, next-generation sequencing and microarrays. Molecular diagnostic

Fibrotic Disease Diagnosis: A Step Towards Painless Detection of Fibrosis

Advances in the field of biotechnology have enabled the development of several minimally invasive / non-invasive approaches for diagnosis of fibrotic disease which include imaging diagnostics and biomarker-based assays. Among the biomarker-based tests, liquid biopsy (based on the analysis of biofluids such as blood, urine and / or plasma), a relatively new concept, has emerged

CDX: The Road Ahead for Personalized Therapies

It is estimated that nearly 50% of prescribed drugs / therapies fail to show adequate clinical benefits. It is also worth highlighting that companion diagnostics (CDX) guided drug development efforts have been estimated to help reduce clinical trial costs by almost 60%. Since the approval of the HercepTest (in 1998) for identifying patients for treatment

Microbiome Therapeutics and Diagnostics: Unlocking the Future Potential

Microbiome therapeutics represent a new frontier in the field of medicine. Currently, there are many probiotics, prebiotics, and medical foods and supplements that are commercially available, and several drug / therapy candidates that claim to be capable of modifying / manipulating the microbiome in order to provide therapeutic benefits. The ‘Human Microbiome Market’ report provides a comprehensive study on the current